NASDAQ: RVPHReviva Pharmaceuticals Holdings Inc Stock
$0.75-0.03 (-3.85%)
Updated Apr 21, 2025
RVPH Price
$0.75
Fair Value Price
$0.39
Market Cap
$34.87M
52 Week Low
$0.49
52 Week High
$4.28
P/E
-0.83x
P/B
42.91x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$29.92M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
18.08
Operating Cash Flow
-$34M
Beta
0.58
Next Earnings
May 12, 2025
Ex-Dividend
N/A
Next Dividend
N/A
RVPH Overview
Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is RP5063, which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company is headquartered in Cupertino, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine RVPH's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
RVPH
Ranked#291 of 462
Ranked#291 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.55 | A | |
| $7.66 | A | |
| $22.02 | A |
Be the first to know about important RVPH news, forecast changes, insider trades & much more!
RVPH News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how RVPH scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
RVPH ($0.75) is overvalued by 89.95% relative to our estimate of its Fair Value price of $0.39 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
RVPH ($0.75) is not significantly undervalued (89.95%) relative to our estimate of its Fair Value price of $0.39 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
RVPH is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more RVPH due diligence checks available for Premium users.
Valuation
RVPH fair value
Fair Value of RVPH stock based on Discounted Cash Flow (DCF)
Price
$0.75
Fair Value
$0.39
Overvalued by
90.97%
RVPH ($0.75) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
RVPH ($0.75) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
RVPH is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
RVPH price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.83x
Industry
-184.27x
Market
27.14x
RVPH price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
42.91x
Industry
4.04x
RVPH is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
RVPH's financial health
Profit margin
Revenue
$0.0
Net Income
-$6.3M
Profit Margin
0%
RVPH's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$15.5M
Liabilities
$14.7M
Debt to equity
18.08
RVPH's short-term assets ($14.68M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RVPH's short-term assets ($14.68M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RVPH's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
RVPH's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$9.1M
Investing
$0.0
Financing
$17.0M
RVPH's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
RVPH vs Biotech Stocks
Reviva Pharmaceuticals Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.